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mammalian visual cortex) (Sanes and
Zipursky 2010). The field needs to know
whether there are other cells that encode
global motion in the protocerebrum and
if so, how they accomplish that task.
Also, the behavioral impact of the mo-
tion-opponent circuit discovered by
Mauss et al. still needs fleshing out. In
theory, investigating visually guided be-
haviors in flies (Maisak et al., 2013) could
be used to implicate this circuit in sepa-
rating self-motion versus object motion
as the fly moves through space.
The implications of the findings in
Mauss et al. extend beyond the parallels
to the mammalian direction-selective cir-
cuit because they also raise several new
ideas about how the brain can use con-
flicting signals to disambiguate sensory
scenes. Not only can this idea be applied
to other types of visual signals, but it may
also provide insight into the general pur-pose of having conflicting sensory inputs
converge in the same targets. Across
multiple sensory modalities, such
convergent computations may result in
the refinement of percepts of the external
world, depending on the specificity with
which they are organized (Sosulski
et al., 2011). In the meantime, the new
results of Mauss et al. indicate that the
brain is highly selective in how it orga-
nizes the flow and transformation of
directional visual information, and they
imply that such stringency may be
essential for accurate decoding of
feature-rich visual scenes.REFERENCES
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Small molecule inhibitors of microtubule dynamics are widely used as cell biology research tools
and clinically as cancer chemotherapeutics. By slight modification to the chemical structure of a
knownmicrotubule inhibitor, combretastatin A-4, Borowiak et al. develop a photoswitchable deriv-
ative that can be turned ‘‘on’’ and ‘‘off’’ with low-intensity light to spatially and temporally control
microtubule dynamics.Microtubules are abundant, dynamic intra-
cellular polymers that perform key func-
tions in important processes such as
mitosis, intracellular transport, and migra-
tion. Microtubule-directed small mole-
cules, which inhibit microtubule dynamics,
are widely used and valuable tools in cell
biology as well as successful chemothera-
peuticsclinically,most likelya result of their
ability to perturb mitosis (Dumontet and
Jordan, 2010). However, due to the abun-
dance of tubulin and the importance of mi-
crotubules not only during mitosis but alsoin interphase, treatment with microtubule-
directed drugs often leads to systemic
side-effects, such as peripheral neuropa-
thies (CarlsonandOcean,2011).Theability
to spatially and temporally control the
activity of such drugs could provide a sig-
nificant advancement in the tolerability,
increasing their overall clinical value. In
this issue of Cell, Borowiak et al. develop
agroupofphotoswitchablemicrotubule in-
hibitors, referred to asPhotostatins (PSTs),
whichcanbe turned ‘‘on’’ and ‘‘off’’withUV
or visible light, respectively (Borowiaket al., 2015). Thus, their work establishes
a novel tool for optically controlling micro-
tubule dynamics in space and time.
Borowiak et al. designed PSTs as ana-
logs of combretastatin A-4, part of a
group of small molecules that bind to the
colchicine-binding domain at the inter-
dimer interface between a- and b-tubulin,
which have been developed particularly
for their vascular-disrupting properties
at the tumor tissue level (Dumontet and
Jordan, 2010). Critically, different com-
bretastatin A-4 isomers have variable162, July 16, 2015 ª2015 Elsevier Inc. 243
Figure 1. Photostatin Activity Can Be Turned ‘‘On’’ and ‘‘Off’’ with Low-Intensity Light to Temporally and Spatially Control Microtubule
Dynamics
(A) In this issue, Borowiak et al. develop and characterize Photostatins (PSTs), small molecule microtubule inhibitors that disassemble microtubules. PST
bioactivity can be turned ‘‘on’’ and ‘‘off’’ with UV (390–430 nm) and green (500–530 nm) light, respectively.
(B) Temporal control of microtubule dynamics using PSTs. In the dark (black), normal microtubule dynamics are observed in the presence of the inactive trans-
PSTs.When exposed toUV light (purple), trans-PSTs isomerize to the active cis-PSTs and rapidly attenuatemicrotubule dynamics. Dynamics are then rescued by
exposure to green light, converting back to inactive trans-PSTs. PST activity is reversible and stable across many on-off cycles.
(C) Single-cell spatial control of microtubule dynamics using PSTs. Microtubule (green lines) dynamics are perturbed in individual cells illuminated with UV light
(purple). UV pulse immediately followed by a rescuing green pulse results in normal dynamics. Cells adjacent to those illuminated with either UV or a combination
of UV/green are unaffected.cytotoxic potencies (Tron et al., 2006).
Taking advantage of this feature, Boro-
wiak et al. replaced the C=C double
bond with an isosteric N=N double
bond, resulting in a molecule that can be
rapidly photoswitched between the trans
(inactive) and cis (active) isomers on a
timescale of seconds using UV (380–
420 nm) and green (500–530 nm) light,
respectively (Figure 1A). Photoisomeriza-
tion is reversible and stable over many
activation-inactivation cycles. Addition-
ally, the active cis-PSTs spontaneously
isomerize to trans-PSTs with a halftime
of 0.75–120 min in the absence of UV illu-
mination (dark regime), ensuring that the
concentration of active cis isomers dimin-
ishes away from the illumination region
without the need for inactivation by green
light.
The development of the PSTs provides
a significant technological advance in
the ability to spatially and temporally con-
trol microtubule assembly dynamics as
well as the cytotoxic effects of microtu-
bule-targeting small molecules. Borowiak
et al. demonstrate the efficacy of PSTs
as microtubule inhibitors in vitro, in single
cells, and in vivo. Consistent with other
agents binding to the colchicine domain
on tubulin (Dumontet and Jordan, 2010;
Stanton et al., 2011), PSTs result in
G2/M phase arrest and eventual cell death
in a concentration dependent manner,
inhibit the assembly of microtubule poly-244 Cell 162, July 16, 2015 ª2015 Elsevier Inmer in vitro, disrupt the cellular microtu-
bule array, and lead to a loss of single
microtubule assembly dynamics. Addi-
tionally, PST-1 competes with colchicine
for binding to tubulin. Most importantly,
Borowiak et al. show that each of the
documented effects of PSTs can be
controlled by the nature of illumination,
exhibiting more than 100-fold less po-
tency when in a dark state, compared to
pulsed illumination with UV light.
To characterize the effects of PSTs on
single microtubule dynamics Borowiak
et al. imaged the end-binding protein
EB3, which recognizes the dynamic
microtubule plus-end with rapid binding/
unbinding kinetics (Maurer et al., 2012),
forming a comet-like signal as the micro-
tubule grows. When illuminated with
pulsed UV light (405 nm), EB3 comet
number, lifetime, speed, and distance
traveled were rapidly reduced. But unlike
other microtubule inhibitors, these dy-
namics can subsequently be recovered
by illumination with pulsed green light
(514 nm), returning close to the control
value (Figure 1B). This inhibition and
recovery of individual microtubule dy-
namics continued through multiple UV/
green light activation/inactivation cycles,
where switching between illuminations
was performed in 2 min phases, thus
demonstrating the novel ability of the
PSTs to be temporally controlled in a
reversible manner within live cells.c.In addition to temporal control, Boro-
wiak et al. also show that bioactivity of
PSTs can be spatially controlled in vivo,
with precision on the order of a single
cell (Figure 1C). Using the C. elegans
embryo model system, single cells were
targeted with millisecond pulses of either
405 nm light alone or a combination
of 405 nm and 514 nm light, in which
a 514 nm rescue pulse was applied
immediately after the activating 405 nm
pulse. Blastomeres were identified and
observed using amCherry-taggedmarker
for the cell membrane and histone H2B.
Illumination was applied when chromo-
somes aligned at the mid-plane during
entry to metaphase. Cells targeted with
the 405 nm light were blocked in meta-
phase, while those targeted with 405 +
514 nm light proceeded through division
normally. Further, untargeted neighboring
cells exhibited normal mitosis and con-
tinued as in a normal embryo in both
cases. Thus, the effects of PSTs can be
reversibly and optically controlled inside
living organisms with single-cell spatial
precision.
The discovery and characterization of
PSTs is an exciting advancement in the
field of small molecule inhibitors and the
field of cell biology research. This technol-
ogy has potential to have an immediate
impact as a research tool to control
microtubule dynamics with single cell pre-
cision on the order of seconds without the
use of complicated microfluidic devices.
Normal progression through mitosis re-
quires multiple steps, including spindle
assembly, proper kinetochore connec-
tions, and chromosome segregation,
each relying on different aspects ofmicro-
tubule dynamics (Inoue´ and Salmon,
1995; London and Biggins, 2014). It would
be interesting to see the effects of acti-
vating PSTs at different points in the cell
cycle. For example, since PSTs induce
microtubule disassembly, activation dur-
ing metaphase could induce depoly-
merization, thus exerting excess disas-
sembly-coupled pulling forces on sister
chromatids, which could be used to
spatially-temporally induce a premature
anaphase-like state for a subset of
kinetochores.
While the cell biological utility is clear, it
remains to be demonstrated that PSTs, or
further derivatives, can succeed clinically,
with a number of issues that need to
be addressed. First, the observed effects
of active cis-PSTs require concentrations
in the micromolar range (typically 0.5–
10 mM), whereas combretastatin A-4, as
well as more clinically relevant drugs,induce similar effects at nanomolar con-
centrations (Jordan and Wilson, 2004).
Further, clinically relevant drug concen-
trations are estimated to be in the nano-
molar range after infusion (Zasadil et al.,
2014). Thus, despite having a greater
than 100-fold higher potency than the
inactive trans isomer, the cis-PST affinity
may be too low to be practical in the clinic.
Further, the need for UV light in photoiso-
merization may limit the clinical applica-
bility as shorter wavelength light has
relatively poor tissue penetration and
may require an implantable light emitting
device depending on the tumor location.
Additionally, prolonged exposure to UV
light, as necessary for maintaining the
cis isomer due to the fast spontaneous
inactivation, could result in additional
cytotoxic effects. While more work will
be necessary for development as a clin-
ical therapy, the work by Borowiak et al.
opens the door for future development
of optically controlled microtubule inhibi-
tors. It will be interesting to see how it
develops in time, and what exciting
discoveries will be made using this new
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